

What is claimed:

1. An antibody or a fragment thereof that binds to human programmed death-ligand 1 (PD-L1) for use in treating cancer, the antibody or fragment thereof comprising:

a heavy chain comprising a complementarity determining region (CDR) H1 comprising any one of SEQ ID NOs: 2, 3, 4, 5, 6 or 7, a CDRH2 comprising any one of SEQ ID NOs: 8, 9, 10, 11, 12, 13 or 14, and a CDRH3 comprising SEQ ID NO: 15; and

a light chain comprising a CDRL1 comprising SEQ ID NO: 20, a CDRL2 comprising SEQ ID NO: 21, and CDRL3 comprising any one of SEQ ID NOs: 22, 75, or 76.

2. The antibody or fragment thereof of claim 1, wherein the cancer is lung cancer, melanoma, renal cell carcinoma (RCC), head and neck cancer, or bladder cancer.

3. The antibody or fragment thereof of claim 2, wherein the lung cancer is non-small cell lung cancer (NSCLC).

4. The antibody or fragment thereof of claim 1, wherein the cancer is a carcinoma.

5. The antibody or fragment thereof of claim 1, wherein the heavy chain comprises any one of SEQ ID NOs: 36, 37, 38, 39, 40 or 41, and the light chain comprises SEQ ID NO: 42.

6. The antibody or fragment thereof of claim 5, wherein the cancer is lung cancer, melanoma, renal cell carcinoma (RCC), head and neck cancer, or bladder cancer.

7. The antibody or fragment thereof of claim 6, wherein the lung cancer is non-small cell lung cancer (NSCLC).

8. The antibody or fragment thereof of claim 5, wherein the cancer is a carcinoma.

9. The antibody or fragment thereof of claim 1, wherein the antibody or fragment thereof binds human PD-L1 with a K_D of at least 8.30×10^{-9} .

10. The antibody or fragment thereof of claim 1, wherein the antibody or fragment thereof is to be administered to the subject in combination with an additional therapeutic compound.

11. The antibody or fragment thereof of claim 10, wherein the additional therapeutic compound is a CAR-T cell, a tumor-targeting antibody, an immune response potentiating modality, or a small molecule drug.

12. An antibody or a fragment thereof that binds to human programmed death-ligand 1 (PD-L1) for use in treating a cancer selected from a carcinoma, lung cancer, melanoma, renal cell carcinoma (RCC), head and neck cancer, or bladder cancer, wherein the antibody or fragment thereof comprises a heavy chain comprising any one of SEQ ID NOs: 36, 37, 38, 39, 40, 41, 51, 52, 53, 54, 55, or 56 and a light chain comprising SEQ ID NO: 42.

13. The antibody or fragment thereof of claim 12, wherein the heavy chain comprises SEQ ID NO: 36.

14. The antibody or fragment thereof of claim 12, wherein the heavy chain comprises SEQ ID NO: 37.

15. The antibody or fragment thereof of claim 12, wherein the heavy chain comprises SEQ ID NO: 38.

16. The antibody or fragment thereof of claim 12, wherein the heavy chain comprises SEQ ID NO: 39.

17. The antibody or fragment thereof of claim 12, wherein the heavy chain comprises SEQ ID NO: 40.

18. The antibody or fragment thereof of claim 12, wherein the heavy chain comprises SEQ ID NO: 41.

19. The antibody or fragment thereof of claim 12, wherein the heavy chain comprises SEQ ID NO: 51.

20. The antibody or fragment thereof of claim 12, wherein the heavy chain comprises SEQ ID NO: 52.

21. The antibody or fragment thereof of claim 12, wherein the heavy chain comprises SEQ ID NO: 53.

22. The antibody or fragment thereof of claim 12, wherein the heavy chain comprises SEQ ID NO: 54.

23. The antibody or fragment thereof of claim 12, wherein the heavy chain comprises SEQ ID NO: 55.

24. The antibody or fragment thereof of claim 12, wherein the heavy chain comprises
SEQ ID NO: 56.

25. The antibody or fragment thereof of claim 12, wherein the cancer is lung cancer.

26. The antibody or fragment thereof of claim 25, wherein the lung cancer is NSCLC.

27. The antibody or fragment thereof of claim 12, wherein the cancer is melanoma.

28. The antibody or fragment thereof of claim 12, wherein the cancer is RCC.

29. The antibody or fragment thereof of claim 12, wherein the cancer is head and neck
cancer.

30. The antibody or fragment thereof of claim 12, wherein the cancer is bladder cancer.

31. The antibody or fragment thereof of claim 12, wherein the cancer is a carcinoma.